NOXXON Pharma AG
Max-Dohrn-Strasse 8-10
Berlin
10589
Germany
Tel: 49-30-726247-0
Fax: 49-30-726247-225
Website: http://www.noxxon.net/
Email: noxxon@noxxon.net
92 articles about NOXXON Pharma AG
-
BioSpace Movers & Shakers, Oct. 29
10/29/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Clinical Catch-Up: September 14-18
9/21/2020
It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies. -
The 2020 virtual meeting of the European Society of Medical Oncology is getting underway and companies are lining up to share information on their latest cancer treatments.
-
NOXXON Presents Latest Clinical Data From Phase 1/2 Nox-a12 / Keytruda® Combination Trial At The ESMO Congress
9/29/2019
NOXXON Pharma N.V. announced the latest clinical results from the Phase 1/2 study of NOX-A12 in combination with Keytruda® in patients with microsatellite-stable, metastatic pancreatic and colorectal cancer in a poster presentation at the European Society for Medical Oncology Congress in Barcelona, Spain.
-
NOXXON Initiates Patient Recruitment for Phase 1/2 Clinical Trial Combining NOX-A12 & Radiotherapy For The Treatment Of Brain Cancer Patients
9/12/2019
NOXXON Pharma N.V. announced the start of recruitment of newly diagnosed brain cancer patients in a Phase 1/2 clinical trial combining the CXCL12 inhibitor NOX-A12 with radiotherapy.
-
NOXXON Announces A Capital Increase Of €1 Million Through A Private Placement Of Shares Without Warrants
8/6/2019
NOXXON Pharma N.V. announced that following discussions with investors it has received letters of intent and binding commitments for long-term investment of €1 million through a private placement plus additional commitment for a future private placement.
-
Noxxon Raises Amount Of € 521 K In Its Rights Issue
7/19/2019
NOXXON Pharma N.V., a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment, announces the results of its rights issue for a limited amount of € 521 K.
-
Results of NOXXON Annual General Shareholders Meeting Held on June 25, 2019
6/27/2019
NOXXON Pharma N.V. announced that the annual general shareholders meeting held on Tuesday, June 25, 2019 at the offices of Freshfields Bruckhaus Deringer LLP, Strawinskylaan 10, 1077 XZ in Amsterdam, the Netherlands approved all voting items.
-
NOXXON Announces Launch of Capital Increase Right Issue for an Amount of Up To € 3.9 M
6/26/2019
NOXXON Pharma N.V. hereby announces the launch and terms of a share capital increase with shareholders’ preferential rights for an amount of up to € 3.9 million.
-
Noxxon Announces Leading International Pharma To Evaluate NOX-A12 In New Indication
6/24/2019
NOXXON Pharma N.V. announced that a leading international pharmaceutical company amongst the top-10 pharmaceutical companies by worldwide revenue[1] has signed an agreement with NOXXON for the purpose of evaluating NOX-A12 in a new indication, which will remain undisclosed for competitive reasons.
-
NOXXON Announces Change Within Supervisory Board
5/3/2019
NOXXON Pharma N.V. announced the appointment of Dr. Maurizio PetitBon, member of the Supervisory Board since September 2016, as Chairman of NOXXON’s Board.
-
Noxxon Pharma N.V. Reports 2018 Financial Results
4/12/2019
NOXXON Pharma N.V. announced its financial results for the fiscal year ending December 31, 2018.
-
The American Association for Cancer Research (AACR) Annual Meeting is taking place in Atlanta. Here’s a look at just a few stories coming out of the meeting.
-
NOXXON PRESENTS UPDATED RESULTS FROM PHASE 1/2 NOX-A12 / KEYTRUDA® COMBINATION TRIAL AT AACR 2019
4/1/2019
NOXXON Pharma N.V. announced the latest update of clinical results from the Phase 1/2 study of NOX-A12 in combination with Keytruda® in patients with microsatellite-stable, metastatic pancreatic and colorectal cancer in a poster presentation at the American Association for Cancer Research Annual Meeting.
-
Noxxon To Present Latest Clinical Data From Nox-a12 / Keytruda® Combination Trial At The 2019 Aacr Annual Meeting
2/28/2019
NOXXON Pharma N.V. announced that the company will present the latest safety, survival and more mature clinical data in patients treated with the CXCL12 inhibitor NOX-A12 in combination with Merck & Co./MSD’s PD-1 inhibitor Keytruda® in metastatic, microsatellite stable pancreatic and colorectal cancer patients.
-
Noxxon Files Application For Phase 1/2 Clinical Trial Combining Nox-a12 & Radiotherapy For The Treatment Of Brain Cancer Patients
2/27/2019
NOXXON Pharma N.V. announced that it has filed the clinical trial application (CTA) with the Federal Institute for Drugs and Medical Devices, to start a Phase 1/2 clinical trial combining NOX-A12 with radiotherapy to treat newly diagnosed brain cancer patients who would not benefit from the current standard of care and whose tumor cannot be fully resected by surgery.
-
NOXXON PUBLISHES A SHAREHOLDER LETTER
2/18/2019
NOXXON Pharma N.V., a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment, published a shareholder letter addressing recent clinical data and outlining its corporate strategy going forward.
-
New Data Published Supporting Monotherapy Activity Of Ccl2 Inhibitor Nox-e36 In An Additional Solid Tumor Type: Liver Cancer
2/1/2019
Data complements previously published results showing activity of NOX-E36 in pancreatic cancer
-
NOXXON ANNOUNCES PARTICIPATION IN THE EAST/WEST CEO FORUM IN SAN FRANCISCO, IN JANUARY 2019
12/20/2018
NOXXON Pharma N.V. announced today that the company will participate in the East/West CEO Forum – an invite-only event that brings together the global leaders of the biopharma community.
-
NOXXON ANNOUNCES KEY FINDINGS THAT NOX-A12 PLUS KEYTRUDA® INDUCES AN IMMUNE RESPONSE AND RESULTS IN CLINICAL BENEFIT FOR PATIENTS
12/14/2018
Findings include stable disease and prolonged time on treatment vs. prior therapy in heavily pretreated metastatic pancreatic and colorectal cancer patients